Ribera Group Implements a Technique to Improve Breast Cancer Diagnosis

The Breast Area of the Ribera healthcare group and its laboratory division, Ribera Lab, have implemented the Mammatyper test, a technique that improves the molecular diagnosis of breast cancer. This test standardizes the evaluation of the four essential biomarkers of the disease, offering precise results in less than eight hours from a minimal amount of tumor sample.

In 2024, 36,300 new cases of breast cancer were diagnosed in Spain, according to the Spanish Society of Medical Oncology (SEOM). Early detection and accurate diagnosis are key to survival, which is why Ribera Lab has incorporated this technology to optimize the molecular subtyping of breast cancer and improve personalized treatments.

Dr. Laia Bernet, coordinator of Pathology at the Ribera group and the Breast Area, explains that Mammatyper is a genetic signature based on the expression of messenger RNA of the key biomarkers, measured with RT-qPCR techniques. Together with Noemí Garrigós, head of Genetics at Ribera Lab, she has driven this advancement, which allows for personalized treatments and reduces the need for chemotherapy in patients who can benefit from other less toxic and more effective therapies.

About Mammatyper

Mammatyper, developed by Sysmex, optimizes the management of breast cancer from diagnosis to treatment monitoring.

About the Breast Area of Ribera

The Breast Area of the Ribera group brings together nearly 100 professionals from various specialties, such as Radiology, Pathology, Oncoplastic Surgery, Oncology, and Nuclear Medicine, among others. Its multidisciplinary approach ensures comprehensive treatment for each patient.

About Ribera Lab

Ribera Lab, the laboratory division of the group, has more than 133 professionals and a central laboratory in Torrellano (Elche). It specializes in cytogenetics, molecular biopathology, and oncohematological diagnosis, providing coverage to the group's hospitals and external healthcare centers.